START FREE TRIAL

Did Apple’s MotionVFX Acquisition Just DEEPEN Its Creator Ecosystem Moat?

Apple (NASDAQ:AAPL) has been busy giving investors plenty to chew on. The company just posted a record quarter, with...

Is Meta’s Moltbook Deal About Social Media … Or The Future Of AI Agents?

Recent developments around Meta Platforms (NASDAQ:META) suggest the company is continuing its aggressive push into artificial intelligence infrastructure and...

Agilent’s $950M Biocare Acquisition Could Unlock A Powerful Recurring Revenue Flywheel

The diagnostics and life sciences equipment industry rarely stands still. But recent developments around Agilent Technologies (NYSE:A) have drawn...

Did AES Just Become Private Equity’s AI Power Bet?

If you blinked this week, you might have missed it. AES Corp. (NYSE:AES) is reportedly in advanced talks to...

Salesforce Just Bought Momentum — But The REAL Play Is Workflow Control!

It has been a busy stretch for Salesforce (NYSE:CRM). Fresh off a strong fiscal third quarter, the company is...

Is Eli Lilly’s Orna Acquisition About RNA Or Something MUCH BIGGER?

Eli Lilly’s move to acquire Orna Therapeutics landed quietly, framed as another pipeline add-on in a year already defined...

Is The Devon + Coterra $21 Billion Merger About Growth — Or Running Out of Rock?

Devon Energy just announced a $21.4 billion all-stock acquisition of Coterra, positioning itself as one of the largest U.S....

Is Apple Outflanking Meta With This Q.AI Move?

Apple acquired Israeli startup Q.AI for close to $2B, locking down patents around “facial skin micro movements” that enable...

Ascendis Pharma Becomes M&A Target Again—European Suitors In Play?

Ascendis Pharma (NASDAQ:ASND) has suddenly become one of the hottest tickers in biotech circles after its shares surged 7.5%...

PayPal Buys Cymbio—What It Really Means For The Future Of AI Shopping

PayPal is acquiring Cymbio, a Tel Aviv-based platform that helps brands sell across agentic commerce channels. This pushes PayPal...

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

Merck (NYSE:MRK) is making headlines again, this time for reportedly circling Revolution Medicines (NASDAQ:RVMD) in what could be one...